All Articles

In the SARC028 phase 2 multicenter trial, reported at the 2017 ASCO Annual Meeting, pembrolizumab achieved encouraging responses in soft tissue sarcoma, especially undifferentiated pleomorphic sarcoma (UPS) and liposarcoma.

Oral cediranib, an investigational VEGF inhibitor, in combination with a PARP or chemotherapy inhibitor, appears to have a survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 ASCO Annual Meeting.

Cancer costs are rising, but the implementation of evidence-based quality improvement strategies in early-stage breast cancer care can reduce costs and improve patient quality of life, according to Angie Meillier, RN, MS, from Abbott Northwestern Piper Breast Center in Minneapolis, MN.

Preliminary data show excellent and durable responses to atezolizumab in 10% of women with triple-negative breast cancer (TNBC), one of the most aggressive and difficult cancers to treat.

The novel combination of the investigational IDO pathway inhibitor indoximod plus pembrolizu­mab led to higher response rates in patients with advanced melanoma than what is seen with pembrolizumab alone, according to interim analysis of a phase 2 clinical trial reported at the 2017 Annual Meeting of AACR.

CAR T-cell therapy achieved excellent responses in an updated report on a series of 50 patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) treated with CAR T-cells at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.

Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic colorectal cancer (CRC), according to final results from the phase 2 HERACLES-A trial.

In the longest follow-up on single-agent nivolumab to date, 5-year overall survival (OS) was 16% in patients with advanced non–small cell lung cancer (NSCLC) in updated results from a phase 1b dose-ranging study (CA209-003).

One of the many responsibilities of a navigator is to facilitate patient education—it is therefore imperative that we educate ourselves on new treatments, distill the information into lay terms, and use that information to effectively educate our patients.

A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.